Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company pioneering oral antiviral therapies for severe viral diseases. This page provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Key resources include: Press releases detailing study results, partnership announcements with research institutions, and financial disclosures. Track updates on COVID-19 therapeutic candidates, hepatitis C treatments, and emerging programs targeting RNA viruses.
All content is sourced directly from company filings and official communications to ensure accuracy. Visitors can expect detailed coverage of Phase 2/3 trial outcomes, FDA interactions, and strategic initiatives advancing antiviral drug development.
Bookmark this page for consolidated access to AVIR's latest scientific advancements and business updates. Check regularly for new developments from Atea's nucleos(t)ide prodrug platform and pipeline expansion efforts.
Atea Pharmaceuticals (NASDAQ: AVIR), a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics, has received a notice from shareholder Bradley L. Radoff regarding his intention to nominate three director candidates for election to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders.
The Company's Nominating and Corporate Governance Committee will evaluate the director candidates according to established practices. Atea's Board will provide its formal recommendation on director nominations in the upcoming definitive proxy statement and WHITE proxy card, to be filed with the SEC. The Company has emphasized that no shareholder action is required at this time, as the 2025 Annual Meeting has not yet been scheduled.
Atea has retained Evercore as financial advisor and Latham & Watkins LLP as legal counsel for this matter.
Atea Pharmaceuticals (AVIR) presented preclinical data for bemnifosbuvir (BEM) at the 38th International Conference on Antiviral Research 2025. The research demonstrated that BEM's metabolism to its active triphosphate is cell-line dependent, highlighting the importance of cell model selection in evaluating antiviral efficacy.
Following successful Phase 2 results in December 2024 and FDA End-of-Phase 2 meeting in January 2025, Atea is launching a global Phase 3 program for HCV treatment in April 2025. The program consists of two open-label trials, each enrolling approximately 800 treatment-naïve patients:
- Non-cirrhotic patients: 8 weeks of BEM/ruzasvir vs 12 weeks of sofosbuvir/velpatasvir
- Compensated cirrhotic patients: 12 weeks of both regimens
The primary endpoint is sustained virologic response 12 weeks post-treatment, measured as HCV RNA below quantitation limit at 24 weeks from treatment start.
Atea Pharmaceuticals (AVIR) announced successful End-of-Phase 2 meeting with FDA for their Hepatitis C Virus (HCV) treatment program. The company plans to initiate global Phase 3 trials in April 2025, enrolling approximately 1,600 patients across two studies testing bemnifosbuvir and ruzasvir combination therapy.
The Phase 2 study showed promising results with 98% SVR12 rate in treatment-adherent patients and 95% in the overall evaluable population after 8 weeks of treatment. The regimen demonstrated strong safety profile with no drug-related serious adverse events.
Key financial highlights for FY2024:
- Cash position: $454.7M (down from $578.1M in 2023)
- R&D expenses: $144.1M (up from $114.2M in 2023)
- G&A expenses: $48.9M
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has scheduled its fourth quarter and full year 2024 financial results conference call for March 6, 2025, at 4:30 p.m. ET.
The company will present financial results and provide a business update through a live conference call and audio webcast. Participants can access the webcast through the Investor Relations section of Atea's website, and telephone participants must register in advance to receive dial-in details. The webcast recording will be available on the company's website for at least 90 days after the event.
Atea Pharmaceuticals (AVIR) has appointed Arthur S. Kirsch to its Board of Directors, effective immediately. Kirsch brings decades of experience in investment banking, capital markets, and extensive knowledge of healthcare and life sciences industries. He currently serves as a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group and has previously held key positions at various global investment banks over his 30-year career.
The appointment aims to strengthen Atea's board as the company advances its strategic priorities, particularly in exploring partnerships for its Phase 3 program involving the combination of bemnifosbuvir and ruzasvir for hepatitis C virus treatment. Kirsch's experience in executing strategic advisory assignments and various public and private financings is expected to contribute to enhancing shareholder value.
Atea Pharmaceuticals (AVIR) announces strategic priorities for 2025, focusing on its global Phase 3 program for HCV treatment. The company plans to initiate trials for its bemnifosbuvir and ruzasvir regimen in Q1 2025, targeting a $3 billion global HCV market.
The company reports $454.7 million in cash and equivalents as of December 31, 2024, with runway extending into 2028. The Phase 3 program will include two open-label trials, each enrolling up to 800 treatment-naïve HCV patients. The trials will evaluate 8-week treatment for non-cirrhotic patients and 12-week treatment for cirrhotic patients, compared to sofosbuvir/velpatasvir.
Market research indicates strong healthcare provider interest in prescribing the regimen and positive payor receptiveness. The treatment aims to address the significant global HCV burden, affecting an estimated 50 million people worldwide with approximately one million new infections annually.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jean-Pierre Sommadossi, PhD, the company's CEO and Founder, will deliver a business update presentation on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco.
The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for at least 90 days following the event.
Atea Pharmaceuticals (NASDAQ: AVIR) is facing pressure from a Concerned Shareholder Group owning approximately 3% of outstanding shares. The group criticizes the company's performance and governance, particularly focusing on Lead Independent Director Franklin M. Berger's recent sale of 359,606 shares at $2.84 per share, near all-time lows and below net cash value.
The shareholders highlight that the Board previously rejected Tang Capital's bid of $5.75 per share plus rights to 80% of net proceeds from drug programs in May 2023. They believe the company can deliver $4.75 per share in cash to shareholders, representing a 50% premium over current price. The group demands Berger's immediate resignation and calls for appointment of a new, shareholder-oriented Lead Independent Director to oversee the ongoing strategic review process with Evercore.
Atea Pharmaceuticals (AVIR) has announced the engagement of Evercore, a global independent investment bank, to explore strategic opportunities aimed at enhancing shareholder value. The primary focus is on identifying potential strategic partnerships for their Phase 3-ready hepatitis C virus (HCV) treatment program. The company has not established a timeline for completing this review process and has not made any definitive decisions. Atea states it will not provide further updates until either the Board of Directors approves a specific course of action, the review concludes, or disclosure becomes necessary. The company emphasizes that there is no guarantee this process will lead to any specific transaction or outcome.
Atea Pharmaceuticals (NASDAQ: AVIR) announced positive Phase 2 study results for its HCV treatment combining bemnifosbuvir and ruzasvir. The study met its primary endpoints with a 98% sustained virologic response rate at 12 weeks post-treatment in treatment-adherent patients after an eight-week regimen.
The treatment showed 95% efficacy in the overall evaluable population, including non-adherent patients. The regimen was generally safe with no drug-related serious adverse events. Non-cirrhotic patients achieved a 99% success rate, while cirrhotic patients showed 88% efficacy.
The company plans to initiate a Phase 3 program in early 2025, following an FDA meeting. The upcoming phase will feature a fixed-dose combination tablet, reducing daily pill count from four to two tablets.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
